Literature DB >> 30375543

Anti-Citrullinated Cyclic Peptide Antibody and Functional Disability Are Associated With Poor Sleep Quality in Rheumatoid Arthritis.

Shamala Rajalingam1, Rajalingham Sakthiswary2, Heselynn Hussein1.   

Abstract

OBJECTIVES: This study aims to determine the predictors of poor sleep quality in rheumatoid arthritis (RA). PATIENTS AND METHODS: This was a monocentric, cross sectional, case-control study which was conducted at the Putrajaya Hospital, Malaysia. We recruited 46 patients with RA (3 males; 43 females; mean age 48.15±14.96) and 46 age and sex-matched healthy controls (3 males; 43 females; mean age 47.11±12.22). RA patients were assessed for their disease activity based on disease activity score in 28 joints, disease damage based on radiographic erosions, and functional status based on Health Assessment Questionnaire Disability Index. The Pittsburgh Sleep Quality Index (PSQI) scores were determined by interviewing all the subjects. Subjects with RA were further subdivided based on their PSQI scores as "good sleepers" with PSQI scores of <5 and "poor sleepers" with PSQI scores of ≥5.
RESULTS: The percentage of poor sleepers was significantly higher among RA patients (47.83% versus 9.57%). Median scores of 5 out of 7 components of the PSQI were higher among RA patients compared to controls. Among poor sleepers with RA, a significantly higher proportion tested positive for anti-citrullinated cyclic peptide autoantibodies (p=0.037). Besides, poor sleepers had significantly higher median Health Assessment Questionnaire Disability Index (p=0.017) than good sleepers. However, both Health Assessment Questionnaire Disability Index (p=0.968) and anti-citrullinated cyclic peptide (p=0.431) were insignificant when entered in the equation of a logistic regression model.
CONCLUSION: The findings of this study demonstrate a link between functional disability, anti-citrullinated cyclic peptide antibodies, and sleep quality in RA.

Entities:  

Keywords:  Anti-citrullinated cyclic peptide; functional capacity; rheumatoid arthritis; sleep quality

Year:  2016        PMID: 30375543      PMCID: PMC6190943          DOI: 10.5606/ArchRheumatol.2017.5960

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  31 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  The Disease Activity Score and the EULAR response criteria.

Authors:  J Fransen; P L C M van Riel
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.

Authors:  George Wells; Tracy Li; Peter Tugwell
Journal:  Ann Rheum Dis       Date:  2010-07-07       Impact factor: 19.103

5.  Improved Sleep Efficiency after Anti-Tumor Necrosis Factor α Therapy in Rheumatoid Arthritis Patients.

Authors:  Regina M Taylor-Gjevre; John A Gjevre; Bindu V Nair; Robert P Skomro; Hyun J Lim
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

6.  The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis.

Authors:  D A Houssien; S P McKenna; D L Scott
Journal:  Br J Rheumatol       Date:  1997-01

7.  The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study.

Authors:  Thomas Roth; Janet M Price; David A Amato; Robert P Rubens; James M Roach; Thomas J Schnitzer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Sleep quality in rheumatoid arthritis, and its association with disease activity in a Korean population.

Authors:  Chang-Nam Son; Go Choi; So-Yeon Lee; Ji-Min Lee; Tae-Han Lee; Hye-Jin Jeong; Chang-Gyu Jung; Ji-Min Kim; Yong-Won Cho; Sang-Hyon Kim
Journal:  Korean J Intern Med       Date:  2015-04-29       Impact factor: 2.884

9.  Effect of intermittent aerobic exercise on sleep quality and sleep disturbances in patients with rheumatoid arthritis - design of a randomized controlled trial.

Authors:  Katrine Løppenthin; Bente Appel Esbensen; Poul Jennum; Mikkel Østergaard; Jesper Frank Christensen; Tanja Thomsen; Julie Schjerbech Bech; Julie Midtgaard
Journal:  BMC Musculoskelet Disord       Date:  2014-02-21       Impact factor: 2.362

10.  Sleep problems and functional disability in children with functional gastrointestinal disorders: an examination of the potential mediating effects of physical and emotional symptoms.

Authors:  Jennifer Verrill Schurman; Craig A Friesen; Hongying Dai; Caroline Elder Danda; Paul E Hyman; Jose T Cocjin
Journal:  BMC Gastroenterol       Date:  2012-10-15       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.